Rx Product News (December 2016)

Pharmacy Times, December 2016 Heart Health, Volume 82, Issue 12

Read about the new Rx Products featured in December.

MytesiMarketed By: Napo Pharmaceuticals

Indication: Mytesi (crofelemer) has been launched as the only FDA-approved treatment for the relief of noninfectious diarrhea in patients with HIV.

Dosage Form: Tablets: 125 mg

For More Information: napopharma.com

EquetroMarketed By: Validus Pharmaceuticals LLC

Indication: The FDA has approved Equetro (carbamazepine) for the treatment of the pain associated with trigeminal neuralgia and as an antiepileptic drug for the treatment of partial seizures with complex symptomatology, generalized tonic-clonic seizures, and mixed seizures.

Dosage Form: Extended-release capsules: 100, 200, and 300 mg

For More Information: equetro.com

Zinplava Marketed By: Merck

Indication: The FDA has approved Zinplava (bezlotoxumab) injection. Zinplava is indicated to reduce recurrence of Clostridium difficile infection (CDI) in patients 18 years and older who are receiving antibacterial drug treatment of CDI and are at high risk for CDI recurrence.

Dosage Form: Injection: 25 mg/mL

For More Information: merck.com

Tecentriq Marketed By: Genentech

Indication: The FDA has approved Tecentriq (atezolizumab) as the first, and only, antiPDL1 cancer immunotherapy for metastatic non—small cell lung cancer.

Dosage Form: Injection: 1200 mg/20 mL (60 mg/mL) solution in a single-dose vial

For More Information: gene.com